Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


For Immunization Managers


Section Navigation
			
			CDC Home








RSVVaxView						Print
																Related Pages
										[RSVVaxView graphic]
Weekly RSV Vaccination DashboardWeekly Respiratory Syncytial Virus (RSV) Vaccination DashboardThe Weekly RSV Vaccination Dashboard is designed to share weekly RSV vaccination data, including coverage estimates and intent for vaccination, using a variety of data sources including surveys, healthcare claims, electronic medical records, and immunization information systems (IIS) data. The Dashboard will be updated weekly as new data become available. Please email to share any feedback.Data Summary
Open All Close All
Adults 60+ Coverage (NIS)
	Data and Charts for Adults 60+ Coverage

**Adults 60+ RSV Vaccination Coverage**
RSV vaccination coverage estimates among adults 60 years and older are based on data from CDC’s National Immunization Survey-Adult COVID Module. Estimates of vaccination coverage are based on respondent self-report.
As of February 3, 2024, an estimated 22.4% (95% Confidence Interval: 21.1%-23.6%) of adults 60 years and older reported having received an RSV vaccine.
An additional 13.3% (11.5%-15.1%) reported that they definitely plan to get vaccinated.
White adults had higher vaccination coverage than adults in all other race and ethnicity groups, with coverage ranging from 9.3% (3.0%-15.7%) among Pacific Islander and Native Hawaiian adults to 25.1% (23.5%-26.7%) among non-Hispanic White adults.
Vaccination coverage has also consistently varied by age, poverty status, health insurance status, urbanicity, gender identity, and chronic medical condition.
Across states and the District of Columbia, receipt of an RSV vaccine was lowest in Mississippi [13.0% (9.8%-16.2%)] and highest in Washington [35.1% (24.7%-45.5%)].
Additional RSV vaccination data by demographic characteristics at the national level and overall estimates by jurisdiction are available.Vaccine Administration and Coverage by Jurisdiction (IIS)
	Data and Charts for Vaccine Administration and Coverage by Jurisdiction

**Vaccine Administration and Coverage by Jurisdiction**
RSV vaccination coverage estimates as of the end of December 2023 based on IIS data submitted to CDC by 43 immunization awardee jurisdictions.
Among the currently reporting 37 state and city IIS jurisdictions, RSV vaccination coverage among adults 60 years and older ranged from 4.6% to 17.9%. Among 6 reporting island jurisdictions, coverage ranged from 0.0% to 3.4%.Adult Vaccinations Administered (IQVIA)
	Data and Charts for Adult Vaccinations Administered

**RSV Vaccinations Administered in Pharmacies and Medical Offices (Data Source: IQVIA)**
RSV vaccinations administered at pharmacies and physician medical offices for adults 60 years and older based on healthcare claims data.
As of January 20, 2024, an estimated 9.02 million doses were administered in pharmacies and an estimated 274,189 doses were administered in physician medical offices to adults 60 years and older.Pregnant Persons Coverage (VSD)
	Data and Charts for Pregnant Persons Coverage

Data for pregnant persons will be updated late in February due to data system updates at VSD sites.
**Pregnant Persons RSV Vaccination Coverage**
RSV vaccination coverage estimates for pregnant persons 18 to 49 years are based on data from CDC’s Vaccine Safety Datalink. Estimates of vaccination coverage are based on electronic health data from multiple integrated health systems.
As of January 27, 2024, among persons who were pregnant and ≥32 weeks gestation since September 22, 2023, overall coverage with the RSV vaccine was 16.2%.
Vaccination coverage was highest among non-Hispanic Asian (22.8%) pregnant persons and lowest among non-Hispanic Black (9.5%) pregnant persons.Nirsevimab Coverage and Intent for Infants (NIS)
	Data and Charts for Nirsevimab Coverage and Intent for Infants

**Monthly Nirsevimab Coverage and Intent for Infants**
Monthly nirsevimab coverage and intent estimates reported by females aged 18-49 years with infants under the age of < 8 months, females aged 18-49 years who are currently pregnant, and females aged 18-49 years who are currently trying to get pregnant, are based on data from CDC’s National Immunization Survey-Adult COVID Module. Estimates of nirsevimab coverage and intent are based on respondent self-report.
As of January 2024, among females with an infant <8 months, 40.5% reported that their infant received nirsevimab.
An additional 21.7% reported that they definitely plan to get nirsevimab for their infant.
Among females who were pregnant in January, 38.2% reported that they definitely plan to get nirsevimab for their infant, and among females who are trying to get pregnant, 44.4% reported that they definitely plan to get nirsevimab for their infant.Nirsevimab Administration and Coverage by Jurisdiction (IIS)
	Data and Charts for Jurisdiction Nirsevimab Administration and Coverage

**Monthly Jurisdiction Nirsevimab Administration and Coverage (IIS)**
Nirsevimab administration and coverage estimates among infants aged <8 months as of the end of December 2023 based on IIS data submitted to CDC by 43 immunization awardee jurisdictions. These data do not include doses administered to infants born on or after October 1, 2023, and information on maternal vaccination status is not reported and not considered when calculating nirsevimab coverage.
Among the currently reporting 37 state and city IIS jurisdictions, nirsevimab coverage among infants <8 months ranged from 1.6% to 20.5%. Among 6 reporting island jurisdictions, coverage ranged from 0.0% to 9.0%.Data & ChartsAdults 60+ Coverage and Intent(Data Source: NIS)Vaccine Administration and Coverage by Jurisdiction(Data Source: IIS)Adult Vaccinations Administered(Data Source:  IQVIA)Pregnant Persons Coverage(Data Source: VSD)Nirsevimab Coverage and Intent for Infants(Data Source: NIS)Nirsevimab Administration and Coverage by Jurisdiction(Data Source: IIS)Related Pages**Prevent RSV**Adults 60 years and older and pregnant persons can protect themselves from RSV.
Learn more about RSV.
							
					
							Last Reviewed:  February 14, 2024						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeImmunization Managers Home
Price Lists & Vaccine Codes
Vaccination Coverageplus icon
ChildVaxView
SchoolVaxView
TeenVaxView
AdultVaxView
FluVaxView
COVIDVaxView
RSVVaxView
Program Contacts
Requirements & Lawsplus icon
State Vaccination Requirementsplus icon
Selected References
HIPAA Overviewplus icon
Access to Patient Records during IQIP & VFC Visits
Perinatal Hepatitis B Prevention
Program Components
Awardee Immunization Websites
Guidelines and Publications


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue